Limits...
Differences of IL-1β Receptors Expression by Immunocompetent Cells Subsets in Rheumatoid Arthritis.

Alshevskaya AA, Lopatnikova JA, Shkaruba NS, Chumasova OA, Sizikov AE, Karaulov AV, Kozlov VA, Sennikov SV - Mediators Inflamm. (2015)

Bottom Line: The effectiveness of the cytokine depends not only on the percentage of receptor-positive cells in an immunocompetent subset but also on the density of receptor expression.The objective of this study was to investigate the expression of IL-1β membrane-bound receptors (IL-1R1 and IL-1R2) in terms of the percentage of receptor-positive cells and the number of receptors per cell in different subsets of immune cells in RA patients before and after a course of basic (excluding anticytokine) therapy and in healthy individuals.The importance of determining both the relative percentage of cells expressing receptors to immunomodulatory cytokines and the number of membrane-bound receptors per cell is highlighted by evidence of unidirectional or multidirectional changing of these parameters according to cell subset and health status.

View Article: PubMed Central - PubMed

Affiliation: Federal State Budgetary Scientific Institution "Research Institute of Fundamental and Clinical Immunology", Yadrintsevskaya Street 14, Novosibirsk 630099, Russia.

ABSTRACT
IL-1β is involved in the induction and maintenance of chronic inflammation in rheumatoid arthritis (RA). Its activity is regulated and induced by soluble and membrane-bound receptors, respectively. The effectiveness of the cytokine depends not only on the percentage of receptor-positive cells in an immunocompetent subset but also on the density of receptor expression. The objective of this study was to investigate the expression of IL-1β membrane-bound receptors (IL-1R1 and IL-1R2) in terms of the percentage of receptor-positive cells and the number of receptors per cell in different subsets of immune cells in RA patients before and after a course of basic (excluding anticytokine) therapy and in healthy individuals. The resulting data indicate differences in the expression of IL-1β receptors among T cells, B cells, and monocytes in healthy volunteers and in rheumatoid arthritis patients. The importance of determining both the relative percentage of cells expressing receptors to immunomodulatory cytokines and the number of membrane-bound receptors per cell is highlighted by evidence of unidirectional or multidirectional changing of these parameters according to cell subset and health status.

No MeSH data available.


Related in: MedlinePlus

Serum content of IL-1 receptor antagonist in healthy individuals (n = 74) and patients with rheumatoid arthritis in the acute phase (n = 28) and after response to treatment (n = 23), in pg/mL. The data are presented as median and interquartile range. The arrows denote significance of intergroup differences, p ≤ 0.05.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4581579&req=5

fig8: Serum content of IL-1 receptor antagonist in healthy individuals (n = 74) and patients with rheumatoid arthritis in the acute phase (n = 28) and after response to treatment (n = 23), in pg/mL. The data are presented as median and interquartile range. The arrows denote significance of intergroup differences, p ≤ 0.05.

Mentions: Furthermore, the system regulating the biological effects of IL-1β also includes IL-1 receptor antagonist, because it competes for binding to cytokine receptors, thus modulating the effect of IL-1β on cells. Hence, it was important to assess the serum content of raIL-1 in RA patients in the acute phase and those who had responded to treatment compared with healthy individuals (Figure 8).


Differences of IL-1β Receptors Expression by Immunocompetent Cells Subsets in Rheumatoid Arthritis.

Alshevskaya AA, Lopatnikova JA, Shkaruba NS, Chumasova OA, Sizikov AE, Karaulov AV, Kozlov VA, Sennikov SV - Mediators Inflamm. (2015)

Serum content of IL-1 receptor antagonist in healthy individuals (n = 74) and patients with rheumatoid arthritis in the acute phase (n = 28) and after response to treatment (n = 23), in pg/mL. The data are presented as median and interquartile range. The arrows denote significance of intergroup differences, p ≤ 0.05.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4581579&req=5

fig8: Serum content of IL-1 receptor antagonist in healthy individuals (n = 74) and patients with rheumatoid arthritis in the acute phase (n = 28) and after response to treatment (n = 23), in pg/mL. The data are presented as median and interquartile range. The arrows denote significance of intergroup differences, p ≤ 0.05.
Mentions: Furthermore, the system regulating the biological effects of IL-1β also includes IL-1 receptor antagonist, because it competes for binding to cytokine receptors, thus modulating the effect of IL-1β on cells. Hence, it was important to assess the serum content of raIL-1 in RA patients in the acute phase and those who had responded to treatment compared with healthy individuals (Figure 8).

Bottom Line: The effectiveness of the cytokine depends not only on the percentage of receptor-positive cells in an immunocompetent subset but also on the density of receptor expression.The objective of this study was to investigate the expression of IL-1β membrane-bound receptors (IL-1R1 and IL-1R2) in terms of the percentage of receptor-positive cells and the number of receptors per cell in different subsets of immune cells in RA patients before and after a course of basic (excluding anticytokine) therapy and in healthy individuals.The importance of determining both the relative percentage of cells expressing receptors to immunomodulatory cytokines and the number of membrane-bound receptors per cell is highlighted by evidence of unidirectional or multidirectional changing of these parameters according to cell subset and health status.

View Article: PubMed Central - PubMed

Affiliation: Federal State Budgetary Scientific Institution "Research Institute of Fundamental and Clinical Immunology", Yadrintsevskaya Street 14, Novosibirsk 630099, Russia.

ABSTRACT
IL-1β is involved in the induction and maintenance of chronic inflammation in rheumatoid arthritis (RA). Its activity is regulated and induced by soluble and membrane-bound receptors, respectively. The effectiveness of the cytokine depends not only on the percentage of receptor-positive cells in an immunocompetent subset but also on the density of receptor expression. The objective of this study was to investigate the expression of IL-1β membrane-bound receptors (IL-1R1 and IL-1R2) in terms of the percentage of receptor-positive cells and the number of receptors per cell in different subsets of immune cells in RA patients before and after a course of basic (excluding anticytokine) therapy and in healthy individuals. The resulting data indicate differences in the expression of IL-1β receptors among T cells, B cells, and monocytes in healthy volunteers and in rheumatoid arthritis patients. The importance of determining both the relative percentage of cells expressing receptors to immunomodulatory cytokines and the number of membrane-bound receptors per cell is highlighted by evidence of unidirectional or multidirectional changing of these parameters according to cell subset and health status.

No MeSH data available.


Related in: MedlinePlus